Rituximab therapy in a patient with low grade B-cell lymphoproliferative disease and concomitant acquired angioedema
- PMID: 25506230
- PMCID: PMC4259552
- DOI: 10.2147/JAA.S68548
Rituximab therapy in a patient with low grade B-cell lymphoproliferative disease and concomitant acquired angioedema
Abstract
Acquired angioedema is often associated with significant morbidity. An underlying lymphatic malignancy, autoimmune disorder, adenocarcinoma, or other malignancy may be present. Screening for these disorders should occur in all patients with acquired angioedema as treatment may result in resolution of angioedema.
Keywords: C1-INH deficiency; complement; ecallantide; hemopathy.
References
-
- Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agnostoni A. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003;82(4):274–281. - PubMed
-
- Branellec A, Bouillet L, Javaud N, et al. Acquired C1-inhibitor deficiency: 7 patients treated with rituximab. J Clin Immunol. 2012;32(5):936–941. - PubMed
-
- Levi M, Hack CE, van Oers MH. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med. 2006;119(8):e3–e5. - PubMed
-
- Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992;71(4):206–215. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
